What is Tirzepatide?
Tirzepatide is a synthetic 39-amino-acid peptide engineered to act as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. It is modified with a fatty diacid side chain that enables albumin binding and once-weekly dosing. Clinically, it is marketed as Mounjaro for type 2 diabetes and Zepbound for chronic weight management.
How does Tirzepatide work?
Tirzepatide improves metabolic signaling through two incretin pathways. GLP-1 receptor activation increases glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and increases satiety. GIP receptor activation appears to further improve insulin sensitivity and may complement central appetite regulation, producing larger average weight-loss responses than older single-incretin therapies in head-to-head trials.
Primary Documented Uses
- Type 2 diabetes treatment under prescription supervision
- Chronic weight management in adults with obesity or overweight plus comorbidity
- Improving cardiometabolic risk factors such as waist circumference and triglycerides
- Ongoing research in obesity-related complications such as sleep apnea and fatty liver disease
Research Summary
Large randomized trials in the SURPASS and SURMOUNT programs show robust reductions in A1c and body weight. In SURMOUNT-1, adults with obesity or overweight receiving tirzepatide achieved substantial mean body-weight reductions over 72 weeks, with the highest dose approaching bariatric-surgery-level average weight loss in some analyses. Research also reports improvements in waist circumference, blood pressure, triglycerides, and cardiometabolic risk markers.
Legal and Regulatory Status
Tirzepatide is FDA-approved as a prescription medication for type 2 diabetes and chronic weight management. Non-prescription or research-chemical versions should not be used clinically. Compounded versions are subject to FDA shortage and compounding rules and should only be considered through licensed medical professionals.
Frequently Asked Questions
What is Tirzepatide?
Tirzepatide is An FDA-approved incretin-based peptide medicine that activates both GIP and GLP-1 receptors for type 2 diabetes and chronic weight management.
How does Tirzepatide work?
Tirzepatide improves metabolic signaling through two incretin pathways. GLP-1 receptor activation increases glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and increases satiety. GIP receptor activation appears to further improve insulin sensitivity and may complement central appetite regulation, producing larger average weight-loss responses than older single-incretin therapies in head-to-head trials.
What does research say about Tirzepatide?
Large randomized trials in the SURPASS and SURMOUNT programs show robust reductions in A1c and body weight. In SURMOUNT-1, adults with obesity or overweight receiving tirzepatide achieved substantial mean body-weight reductions over 72 weeks, with the highest dose approaching bariatric-surgery-level average weight loss in some analyses. Research also reports improvements in waist circumference, blood pressure, triglycerides, and cardiometabolic risk markers.
Is Tirzepatide FDA-approved or legally available?
Tirzepatide is FDA-approved as a prescription medication for type 2 diabetes and chronic weight management. Non-prescription or research-chemical versions should not be used clinically. Compounded versions are subject to FDA shortage and compounding rules and should only be considered through licensed medical professionals.